Sarbani Chaudhuri is the Chief Commercial & Medical Affairs Officer at Rocket Pharma, leading the Marketing, Value & Access, Business Excellence & Operations, and Medical Affairs functions. She is a biopharma executive leader who has built global and U.S. organizations to deliver pioneering therapeutics that have radically transformed patient outcomes and been central to enterprise growth.
With more than 20 years of experience, Sarbani has been at the forefront of disruptive innovation in cell and gene therapies, T-cell engagers, antibody drug conjugates (ADC), and precision therapeutics, through building disease area powerhouses with multiple blockbuster launches, shaping R&D strategies, and business development.
Prior to joining Rocket in April 2025, Sarbani was Vice President at Johnson & Johnson Innovative Medicine leading hematology, where she was a driving force in J&J becoming the top hematology company worldwide in 2024. She led exponential growth of the multi-billion-dollar business, building an industry-leading multiple myeloma powerhouse with DARZALEX® and launching pioneering cell therapy and bispecifics CARVYKTI®, TECVAYLI®, TALVEY®, while expanding into lymphoma and leukemia with a next-generation pipeline.
In her prior role, as Global Head of ENHERTU® and Breast Cancer at AstraZeneca, she established an unparalleled leadership foundation through unlocking multiple HER2-directed tumors. Previously, at Pfizer, she cemented oncology as the company’s growth engine with IBRANCE® and created a rare cardiac and neuromuscular franchise with VYNDAQEL®. Sarbani also held several leadership roles within Novartis’ U.S. sales and marketing organization, playing a key role in strengthening the U.S. go-to-market model.
She received a Bachelor of Engineering degree from VJTI, University of Mumbai, a Master of Business Management from XLRI, Institute of Management Studies, and an MBA from the University of Pennsylvania, with a focus on healthcare management.
Sarbani lives in New Jersey with her son and enjoys inventive cuisine, creative writing, and global travel adventures.
What is Sarbani Chaudhuri's net worth?
The estimated net worth of Sarbani Chaudhuri is at least $973.74 thousand as of May 7th, 2026. Chaudhuri owns 267,510 shares of Rocket Pharmaceuticals stock worth more than $973,736 as of May 12th. This net worth estimate does not reflect any other investments that Chaudhuri may own. Learn More about Sarbani Chaudhuri's net worth.
How do I contact Sarbani Chaudhuri?
Has Sarbani Chaudhuri been buying or selling shares of Rocket Pharmaceuticals?
Over the course of the past ninety days, Sarbani Chaudhuri has sold $67,776.00 in shares of Rocket Pharmaceuticals stock. Most recently, Sarbani Chaudhuri sold 17,650 shares of the business's stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $3.84, for a transaction totalling $67,776.00. Following the completion of the sale, the insider now directly owns 267,510 shares of the company's stock, valued at $1,027,238.40. Learn More on Sarbani Chaudhuri's trading history.
Who are Rocket Pharmaceuticals' active insiders?
Rocket Pharmaceuticals' insider roster includes Elisabeth Bjork (Director), Sarbani Chaudhuri (Insider), Gotham Makker (Director), John Militello (Insider), Aaron Ondrey (CFO), Kinnari Patel (Insider), Jonathan Schwartz (Chief Gene Therapy Officer), Gaurav Shah (CEO), David Southwell (Director), David Southwell (Director), and Martin Wilson (General Counsel & Chief Corporate Officer). Learn More on Rocket Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Rocket Pharmaceuticals?
During the last year, Rocket Pharmaceuticals insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $34,100.00. During the last year, insiders at the biotechnology company sold shares 16 times. They sold a total of 112,910 shares worth more than $391,102.64. The most recent insider tranaction occured on May, 7th when insider Sarbani Chaudhuri sold 17,650 shares worth more than $67,776.00. Insiders at Rocket Pharmaceuticals own 21.3% of the company.
Learn More about insider trades at Rocket Pharmaceuticals. Information on this page was last updated on 5/7/2026.
